Dropping two drug candidates puts Genmab in a better position, says CEO

Genmab made a rare move during Q3 by scrapping two candidates. However, neither CEO Jan van de Winkel nor a Sydbank analyst think the decision will have much of an impact on the company's future.
CEO of Genmab Jan van de Winkel | Photo: PR/Genmab
CEO of Genmab Jan van de Winkel | Photo: PR/Genmab
BY ANDREAS LØNSTRUP, TRANSLATED BY CATHERINE BRETT

It isn't every day that biotech company Genmab has to abandon a drug under development.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading